Epigenomics and ovarian carcinoma

Leonel Maldonado, Mohammad Hoque

Research output: Contribution to journalArticle

Abstract

Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)543-570
Number of pages28
JournalBiomarkers in Medicine
Volume4
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

Biomarkers
Epigenomics
Ovarian Neoplasms
Carcinoma
Histone Deacetylase Inhibitors
Nucleosomes
Methyltransferases
MicroRNAs
Histones
Chromatin
Histone Code
Genes
Monitoring
DNA
DNA Methylation
Therapeutics
Cause of Death
Gene Expression
Research
Neoplasms

Keywords

  • DNA methylation
  • DNA methyltransferase
  • epigenetics
  • histone deacetylase
  • histone modification
  • ovarian cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

Epigenomics and ovarian carcinoma. / Maldonado, Leonel; Hoque, Mohammad.

In: Biomarkers in Medicine, Vol. 4, No. 4, 08.2010, p. 543-570.

Research output: Contribution to journalArticle

Maldonado, Leonel ; Hoque, Mohammad. / Epigenomics and ovarian carcinoma. In: Biomarkers in Medicine. 2010 ; Vol. 4, No. 4. pp. 543-570.
@article{a825549cba244193a4026e41cbbda1c3,
title = "Epigenomics and ovarian carcinoma",
abstract = "Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.",
keywords = "DNA methylation, DNA methyltransferase, epigenetics, histone deacetylase, histone modification, ovarian cancer",
author = "Leonel Maldonado and Mohammad Hoque",
year = "2010",
month = "8",
doi = "10.2217/bmm.10.72",
language = "English (US)",
volume = "4",
pages = "543--570",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Epigenomics and ovarian carcinoma

AU - Maldonado, Leonel

AU - Hoque, Mohammad

PY - 2010/8

Y1 - 2010/8

N2 - Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.

AB - Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.

KW - DNA methylation

KW - DNA methyltransferase

KW - epigenetics

KW - histone deacetylase

KW - histone modification

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=77955630529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955630529&partnerID=8YFLogxK

U2 - 10.2217/bmm.10.72

DO - 10.2217/bmm.10.72

M3 - Article

C2 - 20701443

AN - SCOPUS:77955630529

VL - 4

SP - 543

EP - 570

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 4

ER -